Simple, Prospective and Randomized Trial to Obtain Answers to Questions of Standard of Care: Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab: A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Her2 Negative).
In the REaCT-Vascular Access Her2 negative study, the investigator will use a novel method
to allow comparisons of established standard of care vascular access strategies using the
"integrated consent model" as part of a pragmatic clinical trial.
Determining the optimal vascular access strategy remains an important medical issue for
patients, nurses, physicians and society. A novel method to allow comparison of established
standards of care is needed as part of an increasing internationally mandated incentive to
perform more pragmatic clinic trials.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society